FTRE1 * Stock Overview
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Fortrea Holdings Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$463.70 |
52 Week High | US$504.14 |
52 Week Low | US$463.70 |
Beta | 0 |
11 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -7.83% |
Recent News & Updates
Recent updates
Shareholder Returns
FTRE1 * | MX Life Sciences | MX Market | |
---|---|---|---|
7D | 0% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how FTRE1 * performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how FTRE1 * performed against the MX Market.
Price Volatility
FTRE1 * volatility | |
---|---|
FTRE1 * Average Weekly Movement | n/a |
Life Sciences Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: FTRE1 * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FTRE1 *'s volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2023 | 16,000 | Tom Pike | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Fortrea Holdings Inc. Fundamentals Summary
FTRE1 * fundamental statistics | |
---|---|
Market cap | Mex$38.16b |
Earnings (TTM) | -Mex$1.67b |
Revenue (TTM) | Mex$56.30b |
0.7x
P/S Ratio-22.9x
P/E RatioIs FTRE1 * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FTRE1 * income statement (TTM) | |
---|---|
Revenue | US$3.08b |
Cost of Revenue | US$2.60b |
Gross Profit | US$475.90m |
Other Expenses | US$567.10m |
Earnings | -US$91.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.02 |
Gross Margin | 15.47% |
Net Profit Margin | -2.96% |
Debt/Equity Ratio | 101.5% |
How did FTRE1 * perform over the long term?
See historical performance and comparison